Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 14, Issue 8, 2012, Pages 737-744

  Pan, Changyu ^a   Xing, Xiaoping ^b   Han, Ping ^c   Zheng, Shaoxiong ^d   Ma, Jianhua ^e   Liu, Jingdong ^f   Lv, Xiaofeng ^a   Lu, Juming ^a   Bader, G ^g   Xu, Xiangjin ^h   Bu, Ruifang ⁱ   Ji, Qiuhe ^j   Yang, Wenying ^k   Liu, Zhiming ^l   Zhou, Zhiguang ^m   Zhang, Xiuzhen ⁿ   Guo, Xiaohui ^o   Yang, Huazhang ^p   Hou, Jianming ^q   Lei, Minxiang ^r   Hong, Tianpei ^s   Liu, Libing ^t   more..

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

^d SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^e NANJING MEDICAL UNIVERSITY   (China)

^f Department of Nephrology   (China)

^g NOVARTIS PHARMA AG   (Switzerland)

^h FUZHOU GENERAL HOSPITAL   (China)

ⁱ WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

^j FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^k CHN Japan Friendship Hospital   (China)

^l SECOND MILITARY MEDICAL UNIVERSITY   (China)

^m CENTRAL SOUTH UNIVERSITY   (China)

ⁿ TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^o PEKING UNIVERSITY FIRST HOSPITAL   (China)

^p GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^q FUJIAN PROVINCIAL HOSPITAL   (China)

^r CENTRAL SOUTH UNIVERSITY   (China)

^s PEKING UNIVERSITY THIRD HOSPITAL   (China)

^t FUJIAN MEDICAL UNIVERSITY   (China)

more..

Author keywords

Chinese patients; Diabetes; Dipeptidyl peptidase 4 inhibitor; Microvascular

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; VILDAGLIPTIN;

ABDOMINAL DISCOMFORT; ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHENIA; BODY MASS; CHINESE; CONTROLLED STUDY; COUGHING; DIABETIC NEPHROPATHY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84863312882     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01593.x     Document Type: Article

References (29)

1. Yang W, Lu J, Weng J et al. Prevalence of diabetes among men and women in CHN. N Engl J Med 2010; 362: 1090-1101.
2. Chan JCN, Malik V, Jia W et al. Diabetes in Asia. Epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.
3. Pan C. Diabetes care in CHN: meeting the challenge. World Hosp Health Serv 2005; 41: 29-30, 32.
4. Yan B, Jin-Hua Y, Zhi-hong L et al. Inadequate glycaemic control and antidiabetic therapy among inpatients with type 2 diabetes in Guangdong Province of CHN. Chin Med J 2008; 121: 677-681.
5. Chuang LM, Tsai ST, Huang BY, Tai TY. The status of diabetes control in Asia - a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabet Med 2002; 19: 978-985.
6. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
8. Consoli A, Gomis R, Halimi S et al. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 2004; 30: 509-516.
9. American Diabetes Association Position Statement. Standards of medical care in diabetes. Diabetes Care 2010; 33(Suppl. 1): S11-61.
10. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005.
11. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
12. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084.
13. Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894.
14. Villhauer EB, Brinkman JA, Naderi GB et al. 1-[[(3-hydroxy-1-damantly) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46: 2774-2789.
15. Balas B, Baig MR, Watson C et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007; 92: 1249-1255.
16. Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 2010; 27: 318-326.
17. Ahrén B, Foley JE, Ferrannini E et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2010; 33: 730-732.
18. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132-138.
19. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple dose study. Horm Metab Res 2007; 39: 218-223.
20. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895.
21. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008; 10: 82-90.
22. Ferrannini E, Fonseca V, Zinman B et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009; 11: 157-166.
23. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug naive patients with Type 2 diabetes. Diabet Med 2007; 24: 955-961.
24. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009; 83: 233-240.
25. Kikuchi M, Haneda M, Koya D et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract 2010; 89: 216-223.
26. Iwamoto Y, Kashiwagi A, Yamada N et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab 2010; 12: 700-708.
27. Pan C, Yang W, Barona JP et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008; 25: 435-441.
28. Ahrén B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13: 193-203.
29. Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag 2010; 6: 541-548.